Bertrand Henri Rihn, MD, DSc, professor of biochemistry and molecular biol-ogy  at  Lorraine  University,  France,  is  a  leading  expert  in  the  field  of  particulate  toxicology,  with  research  topics  including  safety  toxicology,  immunotoxicology,  and investigating the transcriptomic changes in macrophages following nanopar-ticle  exposure.  In  addition  to  his  research,  Professor  Rihn  has  also  worked  as  a  clinical toxicologist, and was awarded the Baratz Award (2004) and the E. Taub Award (2011) from the National Academy of Medicine (France). He also served as the president of the French Society of Toxicology from 2007 to 2009, and was a EUROTOX Registered Toxicologist.

• Variety of nanoparticle their synthesis and physicochemical determination. Nanoparticle world: history and introduction to their diversity. Manufacturing nanoparticles: a chemist approach. Manufacturing nanoparticles: a pharmacist approach. Methods for physico-chemical composition determination. Metrology of nanoparticles. Interaction with biological systems. Nanoparticle interaction with proteins: corona formation. Nanoparticle interaction with immune system. Cell uptake and internalization. Response of living systems to nanoparticles. Tools and methods for living system response investigation. Determination of effect biomarkers in cell, e.g. of NCF1 gene. Oxidative stress pathways involved following nanoparticle uptake. Involvement of necrosis, apoptosis or autophagy pathways. Nanoparticle and cell differentiation. Safety assessment of nanoparticle human use. Rodent inhalation studies for nanoparticles. The problem of barrier crossing: skin, placenta and brain barrier. Cell and coculture paradigms in safety assessment. Screening for genotoxicity using toxicogenomics. Nanoparticle and mitochondrion interaction. Medical use of nanoparticles. Nanoparticles and drug delivery: past present and future. Nanoparticles as vehicle of antioxidants. Nanoparticles in imaging for cancer early diagnosis. Phototherapy using drug encapsulated agents in cancer. Nanoparticle therapeutic in degenerative diseases. Nanoparticle in cosmetics. Current use of nanoparticle in the 3 Pharmacopeia.